3-十五烷酮 | 18787-66-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-十五烷酮
• 英文名称: pentadecan-3-one
• 英文别名: Pentadecan-3-on；3-Pentadecanone
• CAS: 18787-66-1
• 化学式: C₁₅H₃₀O
• 分子量: 226.403
• InChiKey: YELXTWKVTZTDCM-UHFFFAOYSA-N

物化性质

• 熔点：
  35.25°C (estimate)
• 沸点：
  293.03°C (estimate)
• 密度：
  0.8184 (estimate)
• 保留指数：
  1668;1675

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  16
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914190090

反应信息

• 作为反应物：
  描述：

  3-十五烷酮 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 乙二醇二甲醚 为溶剂， 反应 10.17h， 生成 3-nitropentadec-3-ene
  参考文献：
  名称：

  Palladium-catalyzed synthesis of substituted nitroolefins

  摘要：

  A one-pot protocol toward several substituted nitroolefins 4 and 6 starting with substituted acetones 2 and 5 was described. A facile process was carried out for the triflation of substituted acetones 2 and 5 with triflic anhydride (Tf2O) under the basic condition (Cs2CO3) and then palladium-catalyzed cross-coupling of enol triflates 3 with NaNO2 and BINAP in the presence of phase-transfer reagents (n-Bu4NBr) under the refluxing 1,2-dimethoxyethane (DME) in acceptable yields. (C) 2013 Elsevier Ltd. All rights reserved,

  DOI：

  10.1016/j.tetlet.2013.04.038
• 作为产物：
  描述：

  1-碘十二烷 在 锌铜偶 、 乙酸乙酯 、 甲苯 作用下， 生成 3-十五烷酮
  参考文献：
  名称：

  Breusch; Baykut, Chemische Berichte, 1953, vol. 86, p. 684,686

  摘要：

  DOI：

文献信息

• [EN] ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'ARGININE MÉTHYLTRANSFÉRASE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2016044626A1

  公开（公告）日：2016-03-24

  Described herein are compounds of Formula (S-I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

  本文描述了式（S-I）的化合物，其药用盐以及药物组合物。本文描述的化合物对抑制精氨酸甲基转移酶活性有用。还描述了利用这些化合物治疗精氨酸甲基转移酶介导的疾病的方法。
• Dominant role of an endothelium-derived hyperpolarizing factor (EDHF)-like vasodilator in the ciliary vascular bed of the bovine isolated perfused eye
  作者：Alister J McNeish、William S Wilson、William Martin

  DOI：10.1038/sj.bjp.0704332

  日期：2001.10

  The roles of the endothelium‐derived nitric oxide, prostacyclin and endothelium‐derived hyperpolarizing factor (EDHF) in mediating vasodilator responses to acetylcholine and bradykinin were assessed in the ciliary vascular bed of the bovine isolated perfused eye preparation. Vasodilatation to acetylcholine or bradykinin was unaffected by the nitric oxide synthase inhibitor, L‐NAME (100 μM), or the cyclo‐oxygenase inhibitor, flurbiprofen (30 μM), but was virtually abolished following treatment with a high concentration of KCl (30 mM), or by damaging the endothelium with the detergent, CHAPS (0.3%, 2 min). Acetylcholine‐induced vasodilatation was unaffected by glibenclamide (10 μM), an inhibitor of ATP‐sensitive K+ channels (K+ATP), but was significantly attenuated by TEA (10 mM), a non‐selective inhibitor of K+ channels. The small conductance calcium‐sensitive K+ channel (SK+Ca) inhibitor, apamin (100 nM), and the large conductance calcium‐sensitive K+ channel (BK+Ca) inhibitor, iberiotoxin (50 nM), had no significant effect on acetylcholine‐induced vasodilatation. In contrast, the intermediate (IK+Ca)/large conductance calcium‐sensitive K+ channel inhibitor, charybdotoxin (50 nM), powerfully blocked these vasodilator responses, and uncovered a vasoconstrictor response. The combination of apamin (100 nM) with a sub‐threshold concentration of charybdotoxin (10 nM) significantly attenuated acetylcholine‐induced vasodilatation, but the combination of apamin (100 nM) with iberiotoxin (50 nM) had no effect. In conclusion, blockade by a high concentration of KCl, by charybdotoxin, or by the combination of apamin with a sub‐threshold concentration of charybdotoxin, strongly suggests that vasodilatation in the bovine isolated perfused eye is mediated by an EDHF. British Journal of Pharmacology (2001) 134, 912–920; doi:10.1038/sj.bjp.0704332

  以下是中文翻译： 评估了来自内皮的NO、前列环素和内皮源性超极化因子（EDHF）在介导乙酰胆碱和缓激肽引发的血管舒张反应中的作用，实验对象为牛孤立灌注眼的睫状血管床。 乙酰胆碱或缓激肽引起的血管舒张不受NO合成酶抑制剂（L-NAME，100 μM）或环氧化酶抑制剂（flurbiprofen，30 μM）的影响，但在给予高浓度KCl（30 mM）或使用洗涤剂CHAPS（0.3%，2 min）破坏内皮后，血管舒张几乎完全消失。 乙酰胆碱诱导的血管舒张不受ATP敏感型K+通道抑制剂（glibenclamide，10 μM）的影响，但在给予非选择性K+通道抑制剂（TEA，10 mM）后显著减弱。 小导电钙敏感型K+通道（SK+Ca）抑制剂（apamin，100 nM）和大导电钙敏感型K+通道（BK+Ca）抑制剂（iberiotoxin，50 nM）对乙酰胆碱诱导的血管舒张无显著影响。相比之下，中/大导电钙敏感型K+通道抑制剂（charybdotoxin，50 nM）强烈阻断了这些血管舒张反应，并揭示了血管收缩反应。 apamin（100 nM）与sub-threshold浓度的charybdotoxin（10 nM）组合显著减弱乙酰胆碱诱导的血管舒张，而apamin（100 nM）与iberiotoxin（50 nM）组合无影响。 综上所述，高浓度KCl、charybdotoxin或apamin与sub-threshold浓度charybdotoxin的组合对血管舒张的强烈阻断，强烈表明牛孤立灌注眼中的血管舒张是由EDHF介导的。 British Journal of Pharmacology (2001) 134, 912–920; doi:10.1038/sj.bjp.0704332
• Double Hydroacylation Reactions of Acyclic and Cyclic α,β-Unsaturated Aldehydes
  作者：Kyung-Mi Cha、Hyejeong Lee、Jung-Woo Park、Yura Lee、Eun-Ae Jo、Chul-Ho Jun

  DOI：10.1002/asia.201100298

  日期：2011.8.1

  Double or quits? double hydroacylation reactions of acyclic and cyclic α,β‐unsaturated aldehydes with olefins afford ketone and diketone products, respectively. Enantiomers are formed whose absolute configurations are controlled by the order of alkene addition.

  两次还是退出？无环和环状α，β-不饱和醛与烯烃的双加氢酰化反应分别提供了酮和二酮产物。形成对映异构体，其绝对构型受烯烃加成的顺序控制。
• [EN] CYCLIC PEPTIDE COMPOUNDS AND RELATED METHODS, SALTS AND COMPOSITIONS<br/>[FR] COMPOSÉS DE PEPTIDES CYCLIQUES ET PROCÉDÉS, SELS ET COMPOSITIONS ASSOCIÉS
  申请人：MERCK SHARP & DOHME

  公开号：WO2015172047A1

  公开（公告）日：2015-11-12

  This invention relates to compounds useful in the preparation of lipopeptides and related methods of preparing and using these compounds.

  本发明涉及在制备脂肽和相关方法中有用的化合物，以及制备和使用这些化合物的相关方法。
• Oxazolidinone penetration enhancing compounds
  申请人：——

  公开号：US04960771A1

  公开（公告）日：1990-10-02

  Compositions for carrying physiologically active agents through body membranes having the structural formula I: ##STR1## where: R=H, Alkyl group containing from 1-18 carbon atoms, cycloalkyl, aryl, aralkyl, alkoxy, hydroxyalkyl, alkoyloxyalkyl, acyloxyalkyl and alkoxyalkyl; X=O and NR.sub.1, where R.sub.1 is selected from H, alkyl, aralkyl acyl group containing from 1-18 carbon atoms, cycloalkyl, hydroxyalkyl, alkoyloxyalkyl acyloxyalkyl and alkoxyalkyl; Y=O and NR.sub.2, where R.sub.2 is selected from H, alkyl, aralkyl, cycloalkyl, acyl group containing from 1-18 carbon atoms, hydroxyalkyl, alkoyloxyalkyl, acyloxyalkyl and alkoxyalkyl; m=2-4; and n=0-4, are disclosed.

  本发明涉及一种用于携带生理活性剂穿过体膜的化合物，其结构式为I：##STR1## 其中：R = H，含有1-18个碳原子的烷基，环烷基，芳基，芳基烷基，烷氧基，羟基烷基，烷氧基烷基，酰氧基烷基和烷氧基烷基；X = O和NR1，其中R1选择自H，烷基，芳基烷基，含有1-18个碳原子的酰基，环烷基，羟基烷基，烷氧基烷基，酰氧基烷基和烷氧基烷基；Y = O和NR2，其中R2选择自H，烷基，芳基烷基，环烷基，含有1-18个碳原子的酰基，羟基烷基，烷氧基烷基，酰氧基烷基和烷氧基烷基；m = 2-4；n = 0-4。